Vanguard Global Advisers
FHTX icon

Vanguard Global Advisers’s Foghorn Therapeutics FHTX Stock Holding History

Vanguard Global Advisers’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.6K Hold
12,833
– – ﹤0.01% 2988
2026
Q1 		$61.3K Buy
+12,833
New +$70.5K ﹤0.01% 2933

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Global Advisers's FHTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 12,833 shares worth $62.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2988.

Vanguard Global Advisers first reported a position in FHTX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Vanguard Global Advisers held 12,833 shares of Foghorn Therapeutics worth $62.6K as of Q2 2026.
  • Vanguard Global Advisers left its Foghorn Therapeutics share count unchanged in Q2 2026.
  • Foghorn Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2988 holding.
  • Vanguard Global Advisers first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.